(18)FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients

BACKGROUND: The efficacy of neoadjuvant chemotherapy regimens in advanced luminal breast cancer patients is difficult to predict. Intrinsic properties of breast tumors, including altered gene expression profile and dynamic evaluation of metabolic properties of tumor cells using positron emission tom...

Descripción completa

Detalles Bibliográficos
Autores principales: de Cremoux, Patricia, Biard, Lucie, Poirot, Brigitte, Bertheau, Philippe, Teixeira, Luis, Lehmann-Che, Jacqueline, Bouhidel, Fatiha A., Merlet, Pascal, Espié, Marc, Resche-Rigon, Matthieu, Sotiriou, Christos, Groheux, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893244/
https://www.ncbi.nlm.nih.gov/pubmed/29662649
http://dx.doi.org/10.18632/oncotarget.24674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893244/
https://www.ncbi.nlm.nih.gov/pubmed/29662649
http://dx.doi.org/10.18632/oncotarget.24674

Ejemplares similares